1. Home
  2. ANAB vs HLX Comparison

ANAB vs HLX Comparison

Compare ANAB & HLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • HLX
  • Stock Information
  • Founded
  • ANAB 2005
  • HLX 1979
  • Country
  • ANAB United States
  • HLX United States
  • Employees
  • ANAB N/A
  • HLX N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • HLX Oilfield Services/Equipment
  • Sector
  • ANAB Health Care
  • HLX Energy
  • Exchange
  • ANAB Nasdaq
  • HLX Nasdaq
  • Market Cap
  • ANAB 951.1M
  • HLX 928.9M
  • IPO Year
  • ANAB 2017
  • HLX 1997
  • Fundamental
  • Price
  • ANAB $36.12
  • HLX $6.73
  • Analyst Decision
  • ANAB Buy
  • HLX Strong Buy
  • Analyst Count
  • ANAB 12
  • HLX 2
  • Target Price
  • ANAB $59.30
  • HLX $10.50
  • AVG Volume (30 Days)
  • ANAB 365.9K
  • HLX 1.5M
  • Earning Date
  • ANAB 10-31-2025
  • HLX 10-22-2025
  • Dividend Yield
  • ANAB N/A
  • HLX N/A
  • EPS Growth
  • ANAB N/A
  • HLX 497.36
  • EPS
  • ANAB N/A
  • HLX 0.28
  • Revenue
  • ANAB $123,164,000.00
  • HLX $1,312,445,000.00
  • Revenue This Year
  • ANAB $24.36
  • HLX N/A
  • Revenue Next Year
  • ANAB N/A
  • HLX $13.14
  • P/E Ratio
  • ANAB N/A
  • HLX $23.82
  • Revenue Growth
  • ANAB 304.17
  • HLX N/A
  • 52 Week Low
  • ANAB $12.21
  • HLX $5.52
  • 52 Week High
  • ANAB $38.39
  • HLX $11.48
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 72.97
  • HLX 55.28
  • Support Level
  • ANAB $33.01
  • HLX $6.58
  • Resistance Level
  • ANAB $35.58
  • HLX $7.97
  • Average True Range (ATR)
  • ANAB 1.67
  • HLX 0.31
  • MACD
  • ANAB -0.05
  • HLX 0.03
  • Stochastic Oscillator
  • ANAB 68.61
  • HLX 32.64

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About HLX Helix Energy Solutions Group Inc.

Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. the Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S.

Share on Social Networks: